Elicera Therapeutics AB (OSTO:ELIC) Ending Cash Position : kr40.71 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Ending Cash Position?

Elicera Therapeutics AB's Ending Cash Position for the quarter that ended in Mar. 2024 was kr40.71 Mil.

Elicera Therapeutics AB's quarterly Ending Cash Position increased from Sep. 2023 (kr25.88 Mil) to Dec. 2023 (kr29.38 Mil) and increased from Dec. 2023 (kr29.38 Mil) to Mar. 2024 (kr40.71 Mil).

Elicera Therapeutics AB's annual Ending Cash Position declined from Dec. 2021 (kr52.39 Mil) to Dec. 2022 (kr43.82 Mil) and declined from Dec. 2022 (kr43.82 Mil) to Dec. 2023 (kr29.38 Mil).

Elicera Therapeutics AB Ending Cash Position Historical Data

The historical data trend for Elicera Therapeutics AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Ending Cash Position Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

0.03

11.57

52.39

43.82

29.38

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial													41.79	40.12	25.88	29.38	40.71

Elicera Therapeutics AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Elicera Therapeutics AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	43.823	+	-14.44
	=	29.38

Elicera Therapeutics AB's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	29.382	+	11.323
	=	40.71

Elicera Therapeutics AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB (OSTO:ELIC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

8E8:Germany

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines